Wednesday, May 12, 2020
JS Genetics Inc
Presentation followed by networking, refreshments & wine bar
JS Genetics Inc. develops and markets proprietary, low cost,
high value DNA diagnostic tests for underserved medical conditions in newborns,
children, and adolescents. This focus grew out of the recognition that most
genetic tests require blood samples, have longer turn-around times, and are
expensive. The company's principal strategy is to internally develop tests using
cheek swabs for sample collection and a PCR based testing platform to bring to
market accurate, convenient, and cost effective DNA screening tests for
adolescents focused in three key areas of developmental disorders:
● Physical Developmental
Disorders: Turner Syndrome, Klinefelter Syndrome, Down's Syndrome
● Cognitive Developmental
● Behavioral Developmental Disorders: Fragile X
The company also has a novel
therapeutic compound under development for the treatment of Periventricular
White Matter Injury (PWMI) in premature infants. That program is currently in
The underlying technology for the company's
Turner syndrome and Dyslexia tests was developed at Yale University and is
exclusively licensed to JS Genetics. Since
2006 the company has received seven SBIR (small business innovation research)
awards totaling $3.4 million. Those grants have been the principal source of
funding for the company's R&D initiatives.
The company's first product, a Turner Syndrome
screening test, is scheduled to be commercially available in the second quarter
of 2010. The company's second product, based on the same underlying technology
as the Turner test, is a screening test for Klinefelter syndrome, the most
common generic abnormality in males. The product is currently in clinical
validation trials and is scheduled to be commercialized in the first quarter of
2011. In the next 18-36 months, the company plans to commercialize
follow-on tests for identification of Fragile X and Trisomy 21 as well as offer
a test for predisposition to Dyslexia.
The BioHaven Entrepreneurship Series features
presentations designed to showcase regionally developed life science
technologies that have progressed along the path to commercialization.
Speakers at the BioHaven events represent both the scientific and business side
of the enterprises.
The programs focus on key success factors of each company,
scientific or technological advantage, business model, and lessons learned in
starting and developing the business. The series also provides social networking
opportunities for scientists, researchers, and businessmen.
For a calendar of all the 2009-10 BioHaven events, click
|President & CEO, JS
Jeff Gruen, M.D.
||Co-Founder & Chairman, Advisory Board, JS
Wednesday, May 12, 2020
3:30 P.M. Registration Open
4:00 P.M. Seminar
5:00 P.M. Networking, Refreshments & Wine Bar
The Anlyan Center auditorium, Yale Medical School.
Directions & Parking:
Registration is free, but please RSVP in advance. E-mail to email@example.com
or call the Yale OCR main number: 203-785-6209.
Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers.
Also sponsored by Elm Street Ventures.
Presented by CURE and the Yale Office of Cooperative Research.